27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of defensives such as healthcare stocks.
FDA news flow of the week was mostly bordering on the negative. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was handed down a complete response letter for its regulatory application seeking expansion of the label of its Nuplazid to include dementia-related psychosis.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The biggest headline of the week was a disclosure by FibroGen, Inc. (NASDAQ:FGEN) that it had fudged data for its anemia drug, which sent its shares down about 48% during the week.
Provention Bio, Inc. (NASDAQ:PRVB) shares came under pressure after it communicated a likely delay in the approval of its Type 1 diabetes treatment candidate teplizumab. The company also said the FDA is not convinced with the pharmacokinetic data from the bridging study of teplizumab that was done to establish its comparability with an existing product from Eli Lilly and Company (NYSE:LLY). Data from Lilly's product was submitted as part of the teplizumab biologic license application.
Two biopharma companies debuted on the Nasdaq following their initial public offerings, raising a combined $221.3 million.
Here are the key catalytic events for the unfolding week:
Conferences
American Association of Cancer Research, or AACR, Annual Meeting 2021 (virtual event): April 10-15
20th Annual Needham Virtual Healthcare Conference: April 12-15
The International Society of Nephrology, or ISN, World Congress of Nephrology, or WCN (virtual event): April 15-19
American Academy of Neurology, AAN, 2021 Meeting: April 17-22
PDUFA Dates
The FDA is scheduled to rule on the new drug application filed by Avenue Therapeutics, Inc. (NASDAQ:ATXI), a Fortress Biotech, Inc. (NASDAQ:FBIO), for its intravenous tramadol for the treatment of moderate to severe pain.
Related Link: After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
Clinical Readouts/Presentations
AACR Meeting Presentations
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI): new translational data from the Phase 1b trial of CMP-001 in subjects with advanced melanoma (Sunday)
Blueprint Medicines Corporation (NASDAQ:BPMC): interim analysis of Phase 2 data for avapritinib in patients with advanced systemic mastocytosis (Sunday)
Mirati Therapeutics, Inc. (NASDAQ:MRTX) and BeiGene, Ltd. (NASDAQ:BGNE): Phase 1b safety/tolerability and preliminary antitumor activity data for Mirati's sitravatinib plus BeiGene's tislelizumab in patients with advanced platinum-resistant ovarian cancer as well as patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma (Sunday)
Beigene: results from the Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (Monday)
Affimed N.V. (NASDAQ:AFMD): positive initial clinical data from an investigator-sponsored Phase 1 study evaluating cord blood-derived natural killercells pre-complexed with Affimed's innate cell engager AFM13 (Tuesday)
WCN Meeting Presentations
Chinook Therapeutics, Inc. (NASDAQ:KDNY): Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing phase 1 study of BION-1301 in immunoglobin A nephropathy, as well as data from the phase 1 intravenous to subcutaneous bioavailability study in healthy volunteers (Thursday)
AAN Meeting Presentations
TG Therapeutics, Inc. (NASDAQ:TGTX): results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in relapsing forms of multiple sclerosis (Saturday)
Revance Therapeutics, Inc. (NASDAQ:RVNC): results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults (Saturday)
Standalone Releases
Auris Medical Holding Ltd. (NASDAQ:EARS) is scheduled to provide a business update on its pre-clinical asset AM-301 on Tuesday. AM-301 is being evaluated for protection against airborne viruses and allergens on Tuesday, April 13, 2021.
Earnings
Theratechnologies Inc. (NASDAQ:THTX) (Wednesday, before the market open)
Affimed N.V. (NASDAQ:AFMD) (Thursday, before the market open)
Centogene N.V. (NASDAQ:CNTG) (Thursday, before the market open)
IPOs
IPO Quiet Period Expiry
Gain Therapeutics, Inc. (NASDAQ:GANX)
Instil Bio, Inc. (NASDAQ:TIL)
Finch Therapeutics Group, Inc. (NASDAQ:FNCH)
Connect Biopharma Holdings Limited (NASDAQ:CNTB)
Universe Pharmaceuticals INC (NASDAQ:UPC)
Movano Inc. (NASDAQ:MOVE)
Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.